<DOC>
	<DOCNO>NCT01192581</DOCNO>
	<brief_summary>The aim study evaluate effectiveness , safety tolerability consistent dosage study drug ( hydroxyethyl starch 130/0.4 sodium chloride injection , Vuloven ) administrate intravenously 7 day .</brief_summary>
	<brief_title>Hydroxyethyl Starch 130/0.4 Sodium Chloride Injection Adjunctive Therapy Subjects With Internal Carotid Artery Hypoperfusion</brief_title>
	<detailed_description>This study recruit 120 male female patient 18 75 year age diagnose brain hypoperfusion within unilateral artery branch internal carotid artery without cerebral infarction . All subject take routine treatment medication . The purpose study evaluate effectiveness , safety tolerability consistent dosage study drug ( hydroxyethyl starch 130/0.4 sodium chloride injection , Vuloven ) administrate intravenously 7 day . Each patient qualify choose participate study randomly assign treatment group ( consistent dose hydroxyethyl starch 130/0.4 sodium chloride injection 500 ml/day , 1000 ml/day 1500 ml/day ) control group ( placebo control ) . The parameter clinic visit include medical history , physical exam , clinical laboratory test , magnetic resonance imaging ( MRI ) , use T1-weighted scan , T2-weighted scan diffusion-weighted imaging ( DWI ) , digital subtraction angiography ( DSA ) , compute tomography ( CT ) perfusion .</detailed_description>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>1 . The degree branch artery stenosis internal carotid artery great equal 70 % confirm DSA . 2 . Before hydroxyethyl starch 130/0.4 sodium chloride injectionadditional treatment , CT perfusion show time peak ( TTP ) lesion area correspond area contralateral hemisphere . 3 . If cerebral infarction appear , time course le 48h , NIH stroke scale : 320 , MRI+DWI show ischemic stroke due large artery atherosclerosis . 1 . Allergy component Hydroxyethyl Starch 2 . Chronic liver disease ( ALT &gt; 120 AST &gt; 120 ) 3 . Chronic renal disease ( Scr &gt; 150 μmol/L ) 4 . Severe heart failure correspond NYHA heart failure classification class III IV , serious arrhythmia , myocardial infarction 5 . Hemorrhagic stroke 6 . Pregnant lactate woman 7 . Patients suffer epilepsy mental sickness 8 . Alcoholism drug abuse 9. hydroxyethyl starch artificial colloidal solution use within 3 month . 10 . Patients participate clinical trial within 6 month 11 . Contraindication CT perfusion imaging ( i.e . contrast allergy , metformin use Creatinine &gt; 160 μmol/l ) 12 . Thrombus low limb vein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>brain hypoperfusion</keyword>
	<keyword>Vuloven</keyword>
	<keyword>compute tomography perfusion</keyword>
</DOC>